Description
A dual inhibitor of VEGFR and FGFR (IC50s = 5-26 and 6-35 nM for VEGFR1-3 and FGFR1-4, respectively); selective for VEGFR1-3 and FGFR1-4 over a panel of 308 kinases at 1 µM; inhibits PDGFRα, PDGFRβ, and DDR1 (IC50s = 35, 169, and 6 nM, respectively), as well as MAP4K4, MINK1, RET, SIK2, YES1, and Tie2 (IC50s = 49, 41, 8, 23, 152, and 174 nM, respectively; inhibits FGFR-dependent proliferation in H1581 lung, SNU-16 stomach, and RT4 bladder cancer cells (IC50s = 104, 132, and 192 nM, respectively) and VEGF-induced tube formation by HUVECs (IC50 = 33 nM); decreases tumor volume in a RT4 mouse xenograft model at 20 and 40 mg/kg; reduces tumor growth and intratumor phosphorylation of FGFR in a SNU-16 mouse xenograft model at 30 mg/kg
Formal name: N-[2′,4′-difluoro-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl][1,1′-biphenyl]-3-yl]-cyclopropanesulfonamide
Synonyms:
Molecular weight: 505.5
CAS: 1430723-35-5
Purity: ≥98%
Formulation: A crystalline solid